Doctors battling a rare strain of Ebola in central Africa will probably need to wait many months for a vaccine to be ready for human trials, the Coalition for Epidemic Preparedness Innovations said, underscoring the challenges health authorities face in combating the outbreak.
CEPI and its partners will start the vaccine development process immediately for multiple candidates, Chief Executive Officer Richard Hatchett said in an interview overnight. However, lab testing and evidence from animal trials will be needed before human studies can begin, he said. Some potential candidates have undergone initial animal testing.
“These are very, very early-stage vaccines,” Hatchett said. “These are not vaccines that have been developed and tested in animals and had any human work that’s been done.”
A World Health Organization technical advisory group is meeting on Tuesday to discuss and provide recommendations on which potential vaccines should be prioritized, WHO said. The rare Bundibugyo strain implicated in this outbreak has no approved treatment and no vaccine. It’s believed to have circulated for weeks before being officially confirmed on May 15, complicating efforts to stop its spread.
Bloomberg